<img src="https://ml.globenewswire.com/Resource/Download/908fb457-7f8e-4a08-9081-5565e3dfb3d7?size=2" nborder="0" align="left" hspace="5" vspace="5" title="22157.jpg" alt="Company Logo"/>Dublin, Aug. 07, 2026 (GLOBE NEWSWIRE) -- The <a href="https://www.researchandmarkets.com/reports/5899673/precision-medicine-collaboration-licensing-deals?utm_source=GNE&amp;utm_medium=PressRelease&amp;utm_code=zwp77c&amp;utm_campaign=2323462+-+Precision+Medicine+Collaboration+and+Licensing+Deals+2019-2026+%7c+Gain+Access+to+Over+1%2c350+Deals+and+Benchmark+with+Confidence&amp;utm_exec=jocamsai" rel="nofollow" target="_blank" title="Precision Medicine Collaboration and Licensing Deals 2019-2026">"Precision Medicine Collaboration and Licensing Deals 2019-2026"</a> has been added to ResearchAndMarkets.com's offering. This report provides a comprehensive and structured analysis of 1350+ precision medicine collaboration and licensing deals, delivering a clear and evidence-based view of how partnerships are designed, negotiated, and executed across the market. The definitive benchmark for precision medicine dealmaking Precision medicine partnering is driven by the integration of data, diagnostics, and targeted therapies, with deal structures reflecting patient stratification strategies and increasingly personalised approaches to treatment. Establish a clear view of market standards The report enables a precise understanding of how precision medicine deals are structured in practice, allowing you to: <ul><li>Benchmark comparable transactions with confidence</li><li>Detailed analysis of upfronts, milestones, and royalty structures across relevant deals</li><li>Define realistic market parameters</li><li>Clear insight into how deal terms vary by technology type, therapeutic alignment, and partner profile</li><li>Support valuation and structuring decisions with evidence</li><li>Ground internal discussions in real transaction data rather than assumptions</li><li>Understand how leading companies approach dealmaking</li><li>Visibility into partner behaviour and recurring deal structures across a data-driven and highly integrated therapeutic landscape</li><li>Full visibility into deal structure and execution</li></ul> Beyond headline deal data, the report provides access to underlying contract documents, enabling a detailed understanding of how agreements are constructed in practice. This includes: <ul><li>Rights granted and retained</li><li>Development and commercialization responsibilities</li><li>Financial structures and payment triggers</li><li>Key contractual provisions and protections</li></ul> This level of transparency is critical to understanding how value, risk, and control are allocated within precision medicine partnerships, particularly where coordination across diagnostics, therapeutics, and data platforms is required. Designed for real-world BD and strategy use The report is widely used to: <ul><li>Structure and benchmark precision medicine transactions</li><li>Prepare for negotiations with well-defined market context</li><li>Evaluate cross-functional partnerships and counterparties</li><li>Support internal strategy with robust, defensible data</li></ul> What's included? <ul><li>1350+ precision medicine collaboration and licensing deals</li><li>Financial terms, including upfronts, milestones, and royalties where disclosed</li><li>Fully searchable deal directory (by company, technology, and therapeutic alignment)</li><li>Direct access to SEC-filed agreements and source documents</li><li>Analysis of deal trends, key transactions, and active dealmakers</li><li>A trusted, evidence-based reference for precision medicine dealmaking</li></ul> Combining comprehensive deal coverage with contract-level insight, this report provides a trusted, evidence-based reference for how precision medicine partnerships are structured, negotiated, and valued. Companies Featured <ul><li>10X Genomics</li><li>Adaptive Biotechnologies</li><li>Agilent Technologies</li><li>Akoya Biosciences</li><li>Alnylam Pharmaceuticals</li><li>Ambry Genetics</li><li>Arbor Biotechnologies</li><li>AstraZeneca</li><li>Azenta Life Sciences</li><li>BeiGene</li><li>Bio-Rad Laboratories</li><li>BioNTech</li><li>Boehringer Ingelheim</li><li>CareDx</li><li>Caris Life Sciences</li><li>Centogene</li><li>Chroma Medicine</li><li>Congenica</li><li>Daiichi Sankyo</li><li>Deep Genomics</li><li>Delfi Diagnostics</li><li>DNAnexus</li><li>Element Biosciences</li><li>Exact Sciences</li><li>Foundation Medicine</li><li>Freenome</li><li>GeneDX</li><li>Genentech</li><li>Guardant Health</li><li>Illumina</li><li>Intellia Therapeutics</li><li>Invitae</li><li>Mission Bio</li><li>Moderna</li><li>Natera</li><li>Novartis</li><li>Olink Proteomics</li><li>Oxford Nanopore Technologies</li><li>Pacific Biosciences</li><li>Parse Biosciences</li><li>Personalis</li><li>Pfizer</li><li>QIAGEN</li><li>Regeneron Pharmaceuticals</li><li>Roche Diagnostics</li><li>SOPHiA Genetics</li><li>Tempus</li><li>Thermo Fisher Scientific</li><li>Twist Bioscience</li><li>Veracyte</li></ul> For more information about this report visit <a href="https://www.researchandmarkets.com/reports/5899673/precision-medicine-collaboration-licensing-deals?utm_source=GNE&amp;utm_medium=PressRelease&amp;utm_code=zwp77c&amp;utm_campaign=2323462+-+Precision+Medicine+Collaboration+and+Licensing+Deals+2019-2026+%7c+Gain+Access+to+Over+1%2c350+Deals+and+Benchmark+with+Confidence&amp;utm_exec=jocamsai" rel="nofollow" target="_blank" title="">https://www.researchandmarkets.com/r/pgmm7h</a> About ResearchAndMarkets.com ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. <pre>CONTACT: 
CONTACT: ResearchAndMarkets.com 
 Laura Wood,Senior Press Manager 
 press@researchandmarkets.com
 For E.S.T Office Hours Call 1-917-300-0470 
 For U.S./ CAN Toll Free Call 1-800-526-8630 
 For GMT Office Hours Call +353-1-416-8900 

</pre> <img alt="" src='https://ml.globenewswire.com/media/YWZmMmM4NDAtZDhkNi00NDU0LWE4NDgtYTNiNWE2MWM4Y2JjLTEwMjY3MzctMjAyNi0wOC0wNy1lbg==/tiny/Research-and-Markets.png' referrerpolicy='no-referrer-when-downgrade' />

GlobeNewswire Inc.

Precision Medicine Collaboration and Licensing Deals 2019-2026 | Gain Access to Over 1,350 Deals and Benchmark with Confidence

Latest news from the world of business and finance – both local and global

MONEY FM 89.3 is Singapore's first and only Business and Personal Finance station, featuring local and international business and financial news.

MONEY FM 89.3

Discover newsletters from our DJs on LinkedIn